Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL

Recruiting now

Conditions studied: DLBCL - Diffuse Large B Cell Lymphoma, Markers of Inflammation

In brief

This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.

Key facts

Study ID

NCT07057765

Run by

Ain Shams University

People needed

40

Starts

2025-05-05

Expected to finish

2026-08-01

Last updated by the study team

2025-07-10

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 years and ≤ 65 years
• Pathologically confirmed, treatment-naïve diffuse large B-cell lymphoma (DLBCL)
• Any stage of disease (nodal or extra-nodal), with or without B symptoms
• Scheduled to receive standard systemic treatment (R-CHOP)
• ECOG performance status 0-2
• Baseline normal:
• Complete blood count (CBC)
• Hepatitis viral markers
• Liver and renal function tests
• Urine analysis
• Echocardiogram
• Additional investigations to exclude current infection if clinically indicated

You may not qualify if…

• History of other concurrent or previous malignancies
• Relapsed or refractory DLBCL
• Uncontrolled comorbid conditions that may interfere with study participation, including:
• Diabetes mellitus
• Autoimmune diseases
• Active infections
• Chronic inflammatory diseases
• Cardiac dysfunction
• Liver cell failure
• Pregnant females

Where it is running

• Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University — Cairo, Cairo Governorate, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.